MX388470B - Administración de potenciadores de regulador de la conductancia transmembrana de fibrosis quística (cftr) deuterados. - Google Patents

Administración de potenciadores de regulador de la conductancia transmembrana de fibrosis quística (cftr) deuterados.

Info

Publication number
MX388470B
MX388470B MX2018003331A MX2018003331A MX388470B MX 388470 B MX388470 B MX 388470B MX 2018003331 A MX2018003331 A MX 2018003331A MX 2018003331 A MX2018003331 A MX 2018003331A MX 388470 B MX388470 B MX 388470B
Authority
MX
Mexico
Prior art keywords
cftr
deuterated
enhancers
administration
cystic fibrosis
Prior art date
Application number
MX2018003331A
Other languages
English (en)
Spanish (es)
Other versions
MX2018003331A (es
Inventor
Virginia Braman
Original Assignee
Vertex Pharmaceuticals Europe Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58387264&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX388470(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vertex Pharmaceuticals Europe Ltd filed Critical Vertex Pharmaceuticals Europe Ltd
Publication of MX2018003331A publication Critical patent/MX2018003331A/es
Publication of MX388470B publication Critical patent/MX388470B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/12Mucolytics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2018003331A 2015-09-21 2016-09-21 Administración de potenciadores de regulador de la conductancia transmembrana de fibrosis quística (cftr) deuterados. MX388470B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562221531P 2015-09-21 2015-09-21
US201562238511P 2015-10-07 2015-10-07
US201662348855P 2016-06-10 2016-06-10
PCT/US2016/052922 WO2017053455A1 (en) 2015-09-21 2016-09-21 Administration of deuterated cftr potentiators

Publications (2)

Publication Number Publication Date
MX2018003331A MX2018003331A (es) 2018-08-16
MX388470B true MX388470B (es) 2025-03-20

Family

ID=58387264

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003331A MX388470B (es) 2015-09-21 2016-09-21 Administración de potenciadores de regulador de la conductancia transmembrana de fibrosis quística (cftr) deuterados.

Country Status (16)

Country Link
US (2) US20180353500A1 (enExample)
EP (2) EP4292588A3 (enExample)
JP (2) JP6849686B2 (enExample)
KR (1) KR102828163B1 (enExample)
CN (1) CN108367002A (enExample)
AU (2) AU2016326441B2 (enExample)
BR (1) BR112018005454A2 (enExample)
CA (1) CA2998911C (enExample)
HK (1) HK1258472A1 (enExample)
IL (2) IL257993A (enExample)
MA (1) MA42950A (enExample)
MX (1) MX388470B (enExample)
RU (1) RU2761344C2 (enExample)
SG (1) SG10201913588YA (enExample)
UA (1) UA124619C2 (enExample)
WO (1) WO2017053455A1 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
HUE047354T2 (hu) 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
RU2692779C2 (ru) 2012-02-27 2019-06-27 Вертекс Фармасьютикалз Инкорпорейтед Фармацевтическая композиция и ее введения
TW202140422A (zh) 2014-10-06 2021-11-01 美商維泰克斯製藥公司 囊腫纖維化症跨膜傳導調節蛋白之調節劑
EP3277647A1 (en) 2015-03-31 2018-02-07 Vertex Pharmaceuticals (Europe) Limited Deuterated vx-661
RU2761344C2 (ru) 2015-09-21 2021-12-07 Вертекс Фармасьютикалз (Юроп) Лимитед Введение дейтерированных усилителей cftr
EP3352758A4 (en) 2015-09-25 2018-08-01 Vertex Pharmaceuticals (Europe) Limited Deuterated cftr potentiators
EP3436446B1 (en) 2016-03-31 2023-06-07 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
JOP20190042B1 (ar) 2016-09-30 2021-08-17 Vertex Pharma مُعدِّل‏ لمنظم موصلية التليف الكيسي عبر الغشاء، وتركيبات صيدلانية، وطرق للعلاج، وعملية لتصنيع المُعدِّل
HRP20201946T1 (hr) 2016-12-09 2021-01-22 Vertex Pharmaceuticals Incorporated Modulator regulatora transmembranske provodljivosti cistične fibroze, farmaceutski sastavi, postupci liječenja, i postupak za dobivanje modulatora
MA54105A (fr) 2017-06-08 2021-09-15 Vertex Pharma Méthodes de traitement de la fibrose kystique
CA3069225A1 (en) * 2017-07-17 2019-01-24 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
BR112020000941A2 (pt) 2017-07-17 2020-07-21 Vertex Pharmaceuticals Incorporated métodos de tratamento para fibrose cística
WO2019028228A1 (en) 2017-08-02 2019-02-07 Vertex Pharmaceuticals Incorporated PROCESSES FOR THE PREPARATION OF PYRROLIDINE COMPOUNDS
WO2019079760A1 (en) 2017-10-19 2019-04-25 Vertex Pharmaceuticals Incorporated CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS
SG11202004264VA (en) 2017-12-01 2020-06-29 Vertex Pharma Processes for making modulators of cystic fibrosis transmembrane conductance regulator
AU2018380426B2 (en) 2017-12-08 2023-05-18 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
IL276662B (en) 2018-02-15 2022-08-01 Vertex Pharma Macrocycles as modulators of the cystic fibrosis transmembrane conductance regulator, their pharmaceutical compounds, their use in the treatment of cystic fibrosis, and a process for their preparation.
WO2019200246A1 (en) 2018-04-13 2019-10-17 Alexander Russell Abela Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
EP3880197B9 (en) 2018-11-14 2025-07-02 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
TWI848092B (zh) 2019-04-03 2024-07-11 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白調節劑
WO2020214921A1 (en) 2019-04-17 2020-10-22 Vertex Pharmaceuticals Incorporated Solid forms of modulators of cftr
FR3096890B1 (fr) 2019-06-07 2021-05-14 H4 Orphan Pharma Utilisation d’une molécule opioïde pour traiter l’œil sec et l’œil allergique.
TWI899097B (zh) 2019-08-14 2025-10-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
TWI867024B (zh) 2019-08-14 2024-12-21 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
KR20220064366A (ko) 2019-08-14 2022-05-18 버텍스 파마슈티칼스 인코포레이티드 Cftr 조절제의 결정질 형태
WO2021030556A1 (en) 2019-08-14 2021-02-18 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
FR3109524B1 (fr) 2020-04-22 2022-04-08 H4 Orphan Pharma Utilisation d’un ligand multifonctionnel pour traiter l’œil sec et les dysfonctionnements des glandes de Meibomius et des glandes lacrymales.
FR3111071B1 (fr) 2020-06-04 2023-01-13 H4 Orphan Pharma Utilisation de ligands multifonctionnels pour traiter les syndromes de détresse respiratoire et le choc cytokinique liés aux infections virales à coronavirus.
CR20230120A (es) 2020-08-07 2023-09-01 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
JP2023537944A (ja) 2020-08-13 2023-09-06 バーテックス ファーマシューティカルズ インコーポレイテッド Cftrモジュレーターの結晶形態
EP4225762A1 (en) 2020-10-07 2023-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076621A1 (en) 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP4225447A1 (en) 2020-10-07 2023-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP4225750A1 (en) 2020-10-07 2023-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US20230373939A1 (en) 2020-10-07 2023-11-23 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076626A1 (en) 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP4225764A1 (en) 2020-10-07 2023-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP4225748A1 (en) 2020-10-07 2023-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076622A2 (en) 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US12324802B2 (en) 2020-11-18 2025-06-10 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2022125826A1 (en) 2020-12-10 2022-06-16 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
US20250221971A1 (en) 2022-02-03 2025-07-10 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
WO2023154291A1 (en) 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
CA3258118A1 (en) 2022-04-06 2023-10-12 Vertex Pharmaceuticals Incorporated MODULATORS OF THE TRANSMEMBRANE CONDUCTANCE REGULATOR IN CYSTIC FIBROSIS
EP4525858A1 (en) 2022-05-16 2025-03-26 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
WO2025076240A1 (en) 2023-10-04 2025-04-10 Vertex Pharmaceuticals Incorporated Solid forms of modulators of cystic fibrosis transmembrane conductance regulator
WO2025076235A1 (en) 2023-10-04 2025-04-10 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2025166342A1 (en) 2024-02-04 2025-08-07 Vertex Pharmaceuticals Incorporated Combination of vanzacaftor, tezacaftor, deutivacaftor for use in treating cystic fibrosis
WO2025171098A1 (en) 2024-02-07 2025-08-14 Vertex Pharmaceuticals Incorporated Compositions for the treatment of cftr-mediated diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
KR100554816B1 (ko) 2001-05-03 2006-02-22 에프. 호프만-라 로슈 아게 비결정질 넬피나비르 메실레이트의 약학 제형
EP1809247A1 (en) 2004-09-29 2007-07-25 Cordis Corporation Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
US20110064811A1 (en) 2005-12-28 2011-03-17 Patricia Hurter Solid forms of N-[2,4-BIS(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
CN102231990B (zh) 2008-08-13 2013-09-25 沃泰克斯药物股份有限公司 N-[2,4-双(1,1-二甲基乙基)-5-羟基苯基]-1,4-二氢-4-氧代喹啉-3-甲酰胺的药物组合物和其给药
NZ603386A (en) * 2010-05-20 2015-02-27 Vertex Pharma Pharmaceutical compositions and administrations thereof
HUE047354T2 (hu) * 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
EA028378B1 (ru) * 2011-05-18 2017-11-30 Консерт Фармасъютиклс Инк. Дейтерированные производные ивакафтора
RU2692779C2 (ru) 2012-02-27 2019-06-27 Вертекс Фармасьютикалз Инкорпорейтед Фармацевтическая композиция и ее введения
WO2014078842A1 (en) * 2012-11-19 2014-05-22 Concert Pharmaceuticals, Inc. Deuterated cftr potentiators
CN109364075B (zh) * 2012-11-21 2021-10-29 顶点制药(欧洲)有限公司 氘化cftr增效剂
US20140221424A1 (en) * 2013-01-30 2014-08-07 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for use in the treatment of cystic fibrosis
RU2761344C2 (ru) 2015-09-21 2021-12-07 Вертекс Фармасьютикалз (Юроп) Лимитед Введение дейтерированных усилителей cftr

Also Published As

Publication number Publication date
NZ741069A (en) 2024-12-20
EP4292588A3 (en) 2024-02-28
US20180353500A1 (en) 2018-12-13
JP2021091723A (ja) 2021-06-17
MX2018003331A (es) 2018-08-16
EP3352757B1 (en) 2023-08-16
IL291517A (en) 2022-05-01
UA124619C2 (uk) 2021-10-20
EP4292588A2 (en) 2023-12-20
IL257993A (en) 2018-05-31
BR112018005454A2 (pt) 2018-10-09
RU2018114447A3 (enExample) 2020-02-21
KR20180058745A (ko) 2018-06-01
CA2998911A1 (en) 2017-03-30
US20200375973A1 (en) 2020-12-03
JP7196217B2 (ja) 2022-12-26
EP3352757A1 (en) 2018-08-01
RU2761344C2 (ru) 2021-12-07
MA42950A (fr) 2018-08-01
EP3352757C0 (en) 2023-08-16
RU2018114447A (ru) 2019-10-23
JP6849686B2 (ja) 2021-03-24
CN108367002A (zh) 2018-08-03
AU2022201135A1 (en) 2022-03-17
HK1258472A1 (zh) 2019-11-15
CA2998911C (en) 2023-05-23
SG10201913588YA (en) 2020-02-27
AU2016326441B2 (en) 2021-11-25
AU2022201135B2 (en) 2024-03-28
WO2017053455A1 (en) 2017-03-30
EP3352757A4 (en) 2018-08-01
KR102828163B1 (ko) 2025-07-02
JP2018534348A (ja) 2018-11-22
AU2016326441A1 (en) 2018-04-19

Similar Documents

Publication Publication Date Title
MX388470B (es) Administración de potenciadores de regulador de la conductancia transmembrana de fibrosis quística (cftr) deuterados.
ZA202204929B (en) Rimegepant for cgrp related disorders
SA518391624B1 (ar) Ror- منظمات جاما
EA201691454A1 (ru) Композиции придопидина модифицированного высвобождения
JOP20200001A1 (ar) كاربوكسأميدات بوصفها معدلات لقنوات الصوديوم
EA201990665A1 (ru) Регуляторы hpk1 на основе производных пиразолопиридина и их применение для лечения рака
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
BR112018076114A2 (pt) composições tópicas de apremilast
MX2023002323A (es) Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
EA202091396A1 (ru) Композиции и способы лечения метаболических состояний
WO2016168553A8 (en) Deuterated obeticholic acid
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
AU2018253538A1 (en) Levodopa formulations for rapid relief of parkinson's disease
MX377032B (es) Compuestos de dihidroquinolinsulfonamida de alquilo.
MX379253B (es) Formulaciones de oximetazolina estabilizadas y sus usos.
EA201892098A1 (ru) Соединение, обладающее ингибирующей мутантную idh активностью, способ его получения и применения
EA202090164A1 (ru) Изотретиноиновые перорально-слизистые композиции и способы их применения
EA201991817A1 (ru) Интраназальная композиция, включающая бетагистин
JOP20190054A1 (ar) مركبات إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
MX374938B (es) Un método para el tratamiento de trastornos del movimiento con befiradol.
EA202090416A1 (ru) Способы лечения симптомов гастропареза с использованием велусетрага
EA201891739A1 (ru) ПРИМЕНЕНИЕ СТИМУЛЯТОРОВ sGC ДЛЯ ЛЕЧЕНИЯ НЕАЛКОГОЛЬНОГО СТЕАТОГЕПАТИТА (NASH)
EA202190247A1 (ru) ПРИМЕНЕНИЕ рГЦ СТИМУЛЯТОРОВ ДЛЯ ЛЕЧЕНИЯ МИТОХОНДРИАЛЬНЫХ ЗАБОЛЕВАНИЙ
EA202090268A1 (ru) Карбоксамиды в качестве модуляторов натриевых каналов
EA202091162A1 (ru) Применение пролекарств рилузола для лечения атаксии